Literature DB >> 18385531

Clinical course of patients with nonclassical 21-hydroxylase deficiency (21-OHD) diagnosed in infancy and childhood.

Ken-ichi Kashimada1, Makoto Ono, Toshikazu Onishi, Satimi Koyama, Takio Toyoura, Kazuhide Imai, Sumitaka Saisho, Shuki Mizutani.   

Abstract

We report four cases of nonclassical 21-hydroxylase deficiency (21-OHD) diagnosed in neonate or early childhood. The four patients comprised a 6-year, 5-month-old male (case 1); a 3-year, 10-month-old female (case 2); a 13-year, 11-month-old female (case 3) and a 17-year, 1-month-old male (case 4). Cases 3 and 4 were siblings. None had any signs of virilization or salt wasting at birth. 21-OHD was diagnosed using ACTH loading test and other adrenal steroid evaluations. Mutations of the CYP21 gene were detected in all patients. Three patients (cases 1, 3 and 4) had positive results in neonatal mass screening. Cases 1 and 2 showed no apparent signs of virilization and were observed without conventional treatment. In cases 3 and 4, because of increased growth velocity and accelerated bone maturation, hydrocortisone administration was initiated from their late infantile period. In spite of hydrocortisone treatment, in case 4, the final height of 159.7 cm was less than his predicted final height. Besides he revealed adrenal insufficiency at the age of 9 years and 2 months old caused by viral infection. Hydrocortisone supplementation therapy may cause adrenal insufficiency in nonclassical patients due to suppression of the hypothalamus-pituitary-adrenal axis. The clinical courses in these cases were various, and it was difficult to predict the appearance of any symptoms of virilization. Careful observation is necessary.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385531     DOI: 10.1507/endocrj.k07e-057

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  4 in total

1.  Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision).

Authors:  Tomohiro Ishii; Kenichi Kashimada; Naoko Amano; Kei Takasawa; Akari Nakamura-Utsunomiya; Shuichi Yatsuga; Tokuo Mukai; Shinobu Ida; Mitsuhisa Isobe; Masaru Fukushi; Hiroyuki Satoh; Kaoru Yoshino; Michio Otsuki; Takuyuki Katabami; Toshihiro Tajima
Journal:  Clin Pediatr Endocrinol       Date:  2022-04-10

2.  Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision).

Authors:  Tomohiro Ishii; Makoto Anzo; Masanori Adachi; Kazumichi Onigata; Satoshi Kusuda; Keisuke Nagasaki; Shohei Harada; Reiko Horikawa; Masanori Minagawa; Kanshi Minamitani; Haruo Mizuno; Yuji Yamakami; Masaru Fukushi; Toshihiro Tajima
Journal:  Clin Pediatr Endocrinol       Date:  2015-07-18

3.  Classic and non-classic 21-hydroxylase deficiency can be discriminated from P450 oxidoreductase deficiency in Japanese infants by urinary steroid metabolites.

Authors:  Yuhei Koyama; Keiko Homma; Maki Fukami; Masayuki Miwa; Kazushige Ikeda; Tsutomu Ogata; Mitsuru Murata; Tomonobu Hasegawa
Journal:  Clin Pediatr Endocrinol       Date:  2016-04-28

4.  Successful pregnancy and live birth in woman with congenital adrenal hyperplasia: A case report.

Authors:  Wei Xiong; Guiqiong Huang; Xiaodong Wang; Shiqiao Tan
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.